Dave Wallace

Feb 19, 2026

‘It’s Time for the Biosimilar Program to Evolve’

As the US biosimilars market sees long-desired changes in areas such as regulatory streamlining and interchangeability, Julie Reed – executive director of the Biosimilars Forum –...
Feb 18, 2026

‘It’s Time for the Biosimilar Program to Evolve’

As the US biosimilars market sees long-desired changes in areas such as regulatory streamlining and interchangeability, Julie Reed – executive director of the Biosimilars Forum –...